Home >> Research Area >>Tyrosine Kinase/Adaptors>>EGFR>> AV-412 free base

AV-412 free base

EGFR/ErbB2 kinase inhibitor CAS# 451492-95-8

AV-412 free base

Catalog No. BCC5120----Order now to get a substantial discount!

Product Name & Size Price Stock
AV-412 free base: 5mg $299 In Stock
AV-412 free base: 10mg Please Inquire In Stock
AV-412 free base: 20mg Please Inquire Please Inquire
AV-412 free base: 50mg Please Inquire Please Inquire
AV-412 free base: 100mg Please Inquire Please Inquire
AV-412 free base: 200mg Please Inquire Please Inquire
AV-412 free base: 500mg Please Inquire Please Inquire
AV-412 free base: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of AV-412 free base

Number of papers citing our products

Chemical structure

AV-412 free base

3D structure

Chemical Properties of AV-412 free base

Cas No. 451492-95-8 SDF Download SDF
PubChem ID 9806229 Appearance Powder
Formula C27H28ClFN6O M.Wt 507
Type of Compound N/A Storage Desiccate at -20°C
Synonyms MP-412 free base
Solubility DMSO : ≥ 50 mg/mL (98.62 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name N-[4-(3-chloro-4-fluoroanilino)-7-[3-methyl-3-(4-methylpiperazin-1-yl)but-1-ynyl]quinazolin-6-yl]prop-2-enamide
SMILES CC(C)(C#CC1=CC2=C(C=C1NC(=O)C=C)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)N4CCN(CC4)C
Standard InChIKey ZAJXXUDARPGGOC-UHFFFAOYSA-N
Standard InChI InChI=1S/C27H28ClFN6O/c1-5-25(36)33-23-16-20-24(30-17-31-26(20)32-19-6-7-22(29)21(28)15-19)14-18(23)8-9-27(2,3)35-12-10-34(4)11-13-35/h5-7,14-17H,1,10-13H2,2-4H3,(H,33,36)(H,30,31,32)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of AV-412 free base

DescriptionPotent inhibitor of EGFR, ErbB2 and Abl receptor tyrosine kinases (IC50 values are 0.5-2, 19 and 41 nM, respectively). Also weak inhibitor of FLT1 and Src. Inhibits EGFR and ErbB2 autophosphorylation in vitro in NSCLC and T-47D breast cancer cell lines, respectively. Inhibits tumor growth of EGFR-overexpressing A431 and ErbB2 overexpressing BT-474 tumor xenografts in mice.

AV-412 free base Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

AV-412 free base Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of AV-412 free base

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.9724 mL 9.8619 mL 19.7239 mL 39.4477 mL 49.3097 mL
5 mM 0.3945 mL 1.9724 mL 3.9448 mL 7.8895 mL 9.8619 mL
10 mM 0.1972 mL 0.9862 mL 1.9724 mL 3.9448 mL 4.931 mL
50 mM 0.0394 mL 0.1972 mL 0.3945 mL 0.789 mL 0.9862 mL
100 mM 0.0197 mL 0.0986 mL 0.1972 mL 0.3945 mL 0.4931 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on AV-412 free base

AV-412 is a dual EGFR/ErbB2 kinase inhibitor with IC50 values of 43nM and 282nM, respectively [1].

In the H1650 and H1975 cell lines containing EGFR mutations, AV-412 inhibits EGFR autophosphorylation and the consequent activation of Akt and Erk at 0.1μM. In the H1781 cell line containing ErbB2 mutation, AV-412 also suppresses the phosphorylation of EGFR as well as ErbB2 and ErbB3. It decreases the phosphorylation of Akt and Erk [2].

AV-412 completely inhibits the tumor growth of both H1650 and H1975 xenografts in nude mice. It is proved that AV-412 suppresses tumor growth via the inhibition of EGFR. Besides that, AV-412 also shows antitumor effects against various tumor models expressing EGFR, ErbB2 or both receptors, such as breast cancer KPL-4, prostate cancer DU145 and lung cancer LC-376. The H520 lung cancer is not sensitive to AV-412 due to the lack of EGFR and ErbB2 in it [2].

References:
[1] Suzuki T, Fujii A, Ohya J, Amano Y, Kitano Y, Abe D, Nakamura H. Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor. Cancer Sci. 2007 Dec;98(12):1977-84. Epub 2007 Sep 18.
[2] Suzuki T, Fujii A, Ohya J, Nakamura H, Fujita F, Koike M, Fujita M. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models. Cancer Sci. 2009 Aug;100(8):1526-31.

Featured Products
New Products
 

References on AV-412 free base

Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.[Pubmed:19459856]

Cancer Sci. 2009 Aug;100(8):1526-31.

Although epidermal growth factor receptor (EGFR) kinase inhibitors are effective for the treatment of non-small cell lung cancer (NSCLC), the emergence of mutations resistant to these inhibitors, such as T790M, has become a clinical problem. Recently, ErbB2 mutations have also been identified in a small number of NSCLC patients. Therefore, novel therapies to overcome these mutations are desirable. We describe the antitumor activity of MP-412 (AV-412), a dual EGFR/ErbB2 kinase inhibitor, against three lung cancer models with EGFR and ErbB2 mutations and also against various human xenografts with overexpression of these receptors. MP-412 inhibited phosphorylation of EGFR and its downstream signaling in NCI-H1650 and NCI-H1975 cell lines, which harbor the E746-A750 deletion and L858R + T790M point mutations, respectively, in EGFR. MP-412 inhibited the growth of these cell lines in vitro and in vivo, whereas the precedent kinase inhibitors lapatinib, erlotinib, and gefitinib were ineffective against NCI-H1975 cells in vivo. Furthermore, MP-412 inhibited ErbB2 signaling in the NCI-H1781 cell line, which harbors the G776V,C insertion in ErbB2, and correlated with its antiproliferation activity. When its antitumor spectrum was further explored in several cancer types overexpressing EGFR or ErbB2, MP-412 showed potent activity in KPL-4 and DU145 xenografts, in which lapatinib was ineffective. MP-412 also inhibited tumor models in which conventional chemotherapies were less effective. These results suggest that MP-412 is a potent dual inhibitor with the potential for treating solid cancers that overexpress EGFR or ErbB2, including NSCLC cells harboring mutations resistant to the first generation of kinase inhibitors.

Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor.[Pubmed:17888033]

Cancer Sci. 2007 Dec;98(12):1977-84.

Epidermal growth factor receptor (EGFR) and ErbB2 are currently recognized as validated target molecules in cancer treatment strategies. MP-412 (AV-412) is a potent dual inhibitor of EGFR and ErbB2 tyrosine kinases, including the mutant EGFR(L858R,T790M), which is clinically resistant to the EGFR-specific kinase inhibitors erlotinib and gefitinib. In an enzyme assay, MP-412 inhibited the EGFR variants and ErbB2 in the nanomolar range with over 100-fold selectivity compared with other kinases, apart from abl and flt-1, which were both moderately sensitive to the compound. In cells, MP-412 inhibited autophosphorylation of EGFR and ErbB2 with IC(50) of 43 and 282 nM, respectively. It also inhibited epidermal growth factor (EGF)-dependent cell proliferation with an IC(50) of 100 nM. Moreover, MP-412 abrogated EGFR signaling in the gefitinib-resistant H1975 cell line, which harbors a double mutation of L858R and T790M in EGFR. In animal studies using cancer xenograft models, MP-412 (30 mg/kg) demonstrated complete inhibition of tumor growth of the A431 and BT-474 cell lines, which overexpress EGFR and ErbB2, respectively. MP-412 suppressed autophosphorylation of EGFR and ErbB2 at the dose corresponding to its antitumor efficacy. When various dosing schedules were applied, MP-412 showed significant effects with daily and every-other-day schedules, but not with a once-weekly schedule, suggesting that frequent dosing is preferable for this compound. Furthermore, MP-412 showed a significant antitumor effect on the ErbB2-overexpressing breast cancer KPL-4 cell line, which is resistant to gefitinib. These studies indicate that MP-412 has potential as a therapeutic agent for the treatment of cancers expressing EGFR and ErbB2, especially those resistant to the first generation of small-molecule inhibitors.

Description

AV-412 free base (MP-412 free base) is an EGFR inhibitor with IC50s of 0.75, 0.5, 0.79, 2.3, 19 nM for EGFR, EGFRL858R, EGFRT790M, EGFRL858R/T790M and ErbB2, respectively.

Keywords:

AV-412 free base,451492-95-8,MP-412 free base,Natural Products,EGFR, buy AV-412 free base , AV-412 free base supplier , purchase AV-412 free base , AV-412 free base cost , AV-412 free base manufacturer , order AV-412 free base , high purity AV-412 free base

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: